Published in Vaccine Weekly, February 20th, 2008
"Most of these approaches have yet to produce clinical responses significantly superior to those of previous standard therapies, although most are well tolerated and elicit relatively high rates of stable disease. Two recently approved agents, a kinase inhibitor and a mTOR inhibitor, are recommended for use as first-line therapies against renal cell...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly